[go: up one dir, main page]

WO2009069014A1 - Lamivudine amorphe et sa préparation - Google Patents

Lamivudine amorphe et sa préparation Download PDF

Info

Publication number
WO2009069014A1
WO2009069014A1 PCT/IB2008/051694 IB2008051694W WO2009069014A1 WO 2009069014 A1 WO2009069014 A1 WO 2009069014A1 IB 2008051694 W IB2008051694 W IB 2008051694W WO 2009069014 A1 WO2009069014 A1 WO 2009069014A1
Authority
WO
WIPO (PCT)
Prior art keywords
lamivudine
amorphous
organic solvent
process according
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/051694
Other languages
English (en)
Inventor
Sayeed Mukhtar
Bhupendra Vashista
Vishwesh Pravinchandra Pandya
Sanjay Mahadeo Gade
Hashim Nizar Poovanathil Nagoor Meeran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2009069014A1 publication Critical patent/WO2009069014A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to amorphous lamivudine.
  • the present invention further relates to a process for the preparation of amorphous lamivudine by spray drying.
  • Lamivudine is a substituted 1,3-oxathiolane and it is presently available in the market as an antiretroviral agent. Lamivudine is a cis-(-)-isomer and it is chemically (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-one of Formula I (A) having the structure as depicted below.
  • U.S. Patent No. 5,905,082 provides a process for preparing lamivudine by enzymatic separation of (+)-cis-4-amino-l-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)- pyrimidine-2-one.
  • lamivudine so obtained has an enantiomeric excess of only about 90%.
  • the process described is tedious and time- consuming and involves an unstirrable mass that needs manual breaking up followed by multiple washings.
  • the product obtained is referred as Form I which has handling and stability problems.
  • US '082 patent also provides a process of converting Form I to Form II in industrial methylated spirit by seeding.
  • WO 03/027106 provides a process for preparing Form II of lamivudine from lamivudine salicylate using ethyl acetate and acetonitrile as solvents and triethylamine as a base.
  • WO '106 application does not disclose any specific method to obtain lamivudine salicylate.
  • WO 2007/119248 provides a process for the preparation of Form III of lamivudine.
  • Form III is prepared by dissolving Form II in water by heating to 45°C and subsequent cooling to 30 0 C. However, the time involved for reducing the temperature from 45°C to 30 0 C varies form 15 minutes to 1 hour 40 minutes. The mixture so obtained is further stirred at 10 0 C for 1 hour, filtered and dried in vacuum at 45°C for 24 hours to obtain Form III. The process also involves optional washing with ethanol or industrial methylated spirit.
  • Form III is also prepared by dissolving Form I in water by heating to 45°C and subsequent cooling to 10 0 C. However, the time involved for reducing the temperature from 45°C to 10 0 C is 10 minutes.
  • Form III is also prepared by stirring a suspension of Form I or Form II in water at 25°C for 24 hours or 48 hours. The mixture is further stirred at 10 0 C for 1 hour, filtered and dried in vacuum at 45°C for 24 hours to obtain Form III.
  • WO 2007/119248 application also provides processes for preparing Form I and Form II of lamivudine.
  • Form I is prepared by dissolving lamivudine in water by heating to 45°C and subsequent cooling to 30 0 C in 0.5 minute.
  • the solid product crystallized as unstirrable mass is broken up, stirred at 10 0 C, filtered and washed with industrial methylated spirit.
  • the washed material is dried in vacuum at 45°C for 24 hours to obtain Form I.
  • Form I is also prepared in a similar way from a mixture of water and denaturated spirit. However, in this process, the time involved for reducing the temperature from 45°C to 30 0 C is 12 minutes and it also involves seeding with Form I crystals.
  • Form II is prepared refluxing lamivudine in ethanol and partially removing the solvent by distillation. The concentrated solution is cooled to 15°C in 35 minutes, stirred at 15°C for 1 hour, filtered and washed with ethanol. The washed product is dried in vacuum at 50 0 C for 12 hours to obtain Form II.
  • WO '248 application does not disclose any method to obtain starting lamivudine for preparing Form I or Form II.
  • lamivudine can be prepared in amorphous form. Such amorphous form can be without the contamination of any crystalline form.
  • a simple process for the preparation of amorphous lamivudine by spray drying By employing present process, lamivudine existing in any crystalline form can be converted into amorphous form.
  • the amorphous lamivudine of the present invention is suitable for preparing pharmaceutical compositions comprising lamivudine.
  • Figure 1 is an X-ray powder diffractogram (XRPD) pattern of amorphous lamivudine.
  • amorphous lamivudine is provided.
  • the amorphous lamivudine has an XRPD pattern substantially as provided in Figure 1.
  • a process for the preparation of amorphous lamivudine comprises, a) dissolving lamivudine in water or an organic solvent, or a mixture thereof, to obtain a solution, and b) removing the solvent from the solution obtained in step a) by spray drying to obtain amorphous lamivudine.
  • the lamivudine used as the starting material has a chemical purity of about 98% or above and a chiral purity of about 99% or above.
  • the pure lamivudine used as the starting material can be in any crystalline form and can be prepared by reducing (lR,2S,5R)-2- isopropyl-5-methylcyclohexyl (2i?,5S)-5-(4-amino-2-oxopyrimidin-l(2H)-yl)-l,3- oxathiolane-2-carboxylate of Formula II,
  • the compound of Formula II can be prepared according to the method provided in U.S. Patent No. 5,905,082.
  • the compound of Formula II is reduced in the presence of water or an organic solvent or a mixture thereof, to obtain lamivudine.
  • the organic solvent is preferably selected from the group consisting of alkanols, ethers and esters.
  • the organic solvent is more preferably selected from the group consisting of methanol, ethanol, tetrahydrofuran, dioxane, isopropyl acetate and ethyl acetate.
  • the reduction is carried out by using a reducing agent.
  • the reducing agent is preferably sodium borohydride, lithium aluminium hydride, lithium borohydride, lithium-tri-ethyl borohydride or lithium- tri- sec- butyl borohydride.
  • the reducing agent is more preferably sodium borohydride.
  • the reduction is preferably carried out in the presence of a phosphate or borate buffer.
  • the buffer is preferably dipotassium hydrogen phosphate.
  • the lamivudine is further treated with salicylic acid.
  • the lamivudine salicylate is isolated from the reaction mixture without the addition of seed lamivudine salicylate.
  • the isolation of lamivudine salicylate is carried out by stirring the reaction mixture in a temperature range from about 10 0 C to about 25°C.
  • the stirring is preferably carried out initially at about 25°C to about 30 0 C and subsequently at about 10 0 C to about 15°C.
  • the stirring can be carried out from about 10 minutes to about 100 hours.
  • the lamivudine salicylate so obtained is treated with a base in the presence of an organic solvent, or a mixture of water and an organic solvent.
  • a mixture of water and an organic solvent is used as a solvent medium while treating lamivudine salicylate with a base.
  • the organic solvent is preferably selected from the group consisting of alkanols, ethers and esters.
  • the organic solvent is more preferably selected from the group consisting of methanol, ethanol, tetrahydrofuran, dioxane, isopropyl acetate and ethyl acetate.
  • the base is preferably an amine, more preferably a tertiary amine.
  • the treatment of lamivudine salicylate with the base is carried out at a temperature of 55°C or below, preferably at about 40 0 C to about 50 0 C.
  • the process is accompanied by stirring to facilitate the liberation of lamivudine as a free base.
  • the lamivudine is isolated from the reaction mixture without adding any seed.
  • the isolation is carried out by stirring the reaction mixture at a temperature of about 0 0 C to about 35°C, preferably at about 15°C to about 30 0 C, followed by filtration, distillation and/or concentration.
  • a washing of lamivudine with an organic solvent can optionally be employed after isolation.
  • the lamivudine so obtained can be further purified by treating with activated charcoal in the presence of an organic solvent.
  • the lamivudine so obtained has a chemical purity of about 98% or above and a chiral purity of about 99% or above.
  • the lamivudine so obtained is dissolved in water or an organic solvent, or a mixture thereof.
  • the organic solvent is selected from the group consisting of alcohols, ketones, esters, ethers and nitriles.
  • the organic solvent is preferably selected from the group consisting of methanol, ethanol, n-propanol, 2-propanol, n-butanol, sec-butanol, ethyl acetate, acetone, acetonitrile and tetrahydrofuran.
  • the lamivudine is preferably dissolved in a mixture of water and an organic solvent.
  • the ratio of water and the organic solvent can be 1:1 to 1:100.
  • the dissolution process can be accompanied by heating the reaction mixture to ensure complete dissolution.
  • the heating may be carried out to attain a temperature of about 35°C to about reflux temperature.
  • the solvent is removed from the solution so obtained by spray drying in a spray drier.
  • the solution may optionally be filtered prior to spray drying. .
  • the inlet and outlet temperatures, feed rate, and atomizer type of the spray drier can be adjusted to optimize output and particle size.
  • the air inlet temperature is preferably controlled from about 75°C to about 95°C.
  • the outlet temperature is preferably controlled from about 50 0 C to about 70 0 C.
  • An inert gas such as nitrogen can also be used as a carrier gas.
  • the amorphous product is collected from the spray dryer and optionally further dried under vacuum to obtain amorphous lamivudine.
  • a pharmaceutical composition comprising amorphous lamivudine is provided which optionally contains one or more excipients.
  • a method of treating HIV or HBV infections comprises administering to a human in need thereof a therapeutically effective amount of amorphous lamivudine.
  • Powder XRD of the samples were determined by using Panalytical X' Pert Pro X- Ray Powder Diffractometer in the range 3-40 degree 2 theta and under tube voltage and current of 45 Kv and 40 mA respectively. Copper radiation of wavelength 1.54 angstrom and Xceletor detector was used. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
  • Dipotassium hydrogen orthophosphate (205.5 g) was added to deionised water (423 mL) and stirred at 25° to 3O 0 C to obtain a solution.
  • the solution was cooled to 17° to 22 0 C, followed by the addition of denaturated spirit (900 mL) at the same temperature and stirred for 5 minutes.
  • the p ⁇ of the combined organic layer was adjusted to 6.0 to 6.5 with dilute hydrochloric acid (20 rnL; prepared by mixing 10 rnL of concentrated hydrochloric acid with 10 rnL of deionised water) at 18° to 25 0 C, followed by stirring for 10 minutes at the same temperature.
  • the pH of the reaction mixture was adjusted to 8.0 to 8.5 with aqueous sodium hydroxide solution (28 mL; prepared by dissolving 2.1 g of sodium hydroxide in 27 mL of deionised water) at 18° to 25 0 C.
  • the reaction mixture was concentrated under vacuum at about 55 0 C till the residual volume was about 375 mL.
  • Deionised water 300 mL was added to the concentrated reaction mixture at 25° to 3O 0 C and stirred for 10 minutes.
  • the reaction mixture was washed with toluene (2 X 150 mL) at 25° to 3O 0 C and the toluene layer was extracted with deionised water (150 mL) at 25° to 30 0 C.
  • the aqueous layers were combined and salicylic acid (57 g) was added at 25° to 30 0 C.
  • Deionised water 150 mL was added to the reaction mixture and heated to 78° to 82 0 C to get a clear solution.
  • the reaction mixture was cooled to 25° to 3O 0 C over a period of 2 hours and stirred at the same temperature for 4 hours.
  • the reaction mixture was further cooled to 10° to 15 0 C and stirred for 2 hours at 10° to 15 0 C.
  • the solid was filtered, washed with deionised water (150 mL) and dried by suction.
  • the solid so obtained was washed with methanol (90 mL, pre-cooled to 5° to 1O 0 C) and dried at 45° to 5O 0 C in hot air oven to obtain the title compound.
  • Lamivudine salicylate 120 g was added to a mixture of ethyl acetate (720 mL) and water (6 mL) at 25° to 35°C. The reaction mixture was heated to 45° to 50 0 C, followed by the addition of triethylamine (104.76 g) over 30 minutes at 45° to 50 0 C. The reaction mixture was stirred for 4 hours at the same temperature and cooled to 25° to 30 0 C. The reaction mixture was stirred for further 30 minutes at 25° to 30 0 C, filtered and dried by suction. The solid obtained was washed with ethyl acetate.
  • Ethyl acetate 600 mL was added to the washed solid and heated to 50° to 55°C. The mixture was stirred at 50° to 55°C for 15 minutes, cooled to 25° to 3O 0 C and stirred for further 30 minutes. The solid was filtered at 25° to 3O 0 C, washed with ethyl acetate (60 mL) and dried under vacuum at 45° to 50 0 C to obtain lamivudine. Lamivudine (60 g) so obtained was added to absolute alcohol (1.2 L) at 25° to 35°C. The reaction mixture was heated to 75° to 78°C and stirred to obtain a solution.
  • Activated carbon (6 g) was added to the solution so obtained at 75° to 78°C, stirred for 30 minutes at the same temperature and filtered through Celite bed at the same temperature.
  • the carbon bed was washed with absolute alcohol (60 mL; preheated to 75° to 76°C) and the reaction mixture was concentrated under vacuum to obtain a volume of about 300 mL.
  • the concentrated reaction mixture was heated to 74° to 76°C, stirred for 15 minutes and cooled to 20° to 25°C in 1 hour time.
  • the reaction mixture was further cooled to 5° to 10 0 C in 1 hour time and stirred for 30 minutes.
  • the solid was filtered, washed with absolute alcohol (30 mL, pre-cooled to 5° to 10 0 C) and dried under vacuum at 50° to 55°C to obtain the title compound.
  • Crystalline Form II of lamivudine (30 g) as prepared in Example 1 was dissolved in a mixture of methanol (210 mL) and water (90 mL) at 45° to 50 0 C.
  • the resultant solution was spray dried (Inlet temperature: 85° to 90 0 C; Outlet temperature: 60° to 65°C).
  • the amorphous powder so obtained was dried at 45° to 50 0 C under vacuum for 3 to 4 hours to obtain the title compound having an XRPD pattern as depicted in Figure 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de la lamivudine amorphe et sa méthode de préparation par séchage par pulvérisation.
PCT/IB2008/051694 2007-11-29 2008-04-30 Lamivudine amorphe et sa préparation Ceased WO2009069014A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2504DE2007 2007-11-29
IN2504/DEL/2007 2007-11-29

Publications (1)

Publication Number Publication Date
WO2009069014A1 true WO2009069014A1 (fr) 2009-06-04

Family

ID=39818470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/051694 Ceased WO2009069014A1 (fr) 2007-11-29 2008-04-30 Lamivudine amorphe et sa préparation

Country Status (1)

Country Link
WO (1) WO2009069014A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101953799A (zh) * 2010-09-29 2011-01-26 天津市医药集团技术发展有限公司 一种拉米夫定散剂及其制备方法
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20030004130A1 (en) * 2001-05-24 2003-01-02 Malcolm Ross Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
WO2007119248A1 (fr) * 2006-04-18 2007-10-25 Lupin Limited Nouvelle forme cristalline de la lamivudine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20030004130A1 (en) * 2001-05-24 2003-01-02 Malcolm Ross Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
WO2007119248A1 (fr) * 2006-04-18 2007-10-25 Lupin Limited Nouvelle forme cristalline de la lamivudine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANSHUMAN A AMBIKE ET AL: "Spray-Dried Amorphous Solid Dispersions of Simvastatin, a Low Tg Drug: In Vitro and in Vivo Evaluations", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 22, no. 6, 1 June 2005 (2005-06-01), pages 990 - 998, XP019370876, ISSN: 1573-904X *
GUPTA P ET AL: "SPRAY DRYING FOR GENERATION OF A TERNARY AMORPHOUS SYSTEM OF CELECOXB, PVP, AND MEGLUMINE", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 10, no. 2, 1 January 2005 (2005-01-01), pages 273 - 281, XP008068290, ISSN: 1083-7450 *
HANCOCK B C ET AL: "CHARACTERISTICS AND SIGNIFICANCE OF THE AMORPHOUS STATE IN PHARMACEUTICAL SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCE, US, vol. 86, no. 1, 1 January 1997 (1997-01-01), pages 1 - 12, XP000929450, ISSN: 0022-3549 *
YU L: "AMORPHOUS PHARMACEUTICAL SOLIDS: PREPARATION, CHARACTERIZATION AND STABILIZATION", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 48, no. 1, 16 May 2001 (2001-05-16), pages 27 - 42, XP009065056, ISSN: 0169-409X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101953799A (zh) * 2010-09-29 2011-01-26 天津市医药集团技术发展有限公司 一种拉米夫定散剂及其制备方法
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor

Similar Documents

Publication Publication Date Title
EP2227465A1 (fr) Forme cristalline i de lamivudine et sa préparation
WO2024017170A1 (fr) Forme cristalline de s-(-)-nicotine(-)-dibenzoyl-l-tartrate, procédé de préparation et utilisation
WO2009037538A2 (fr) Procédé de préparation de lamivudine de forme i
WO2009069014A1 (fr) Lamivudine amorphe et sa préparation
JP2013527239A (ja) イクサベピロンの固体形
EP2850064B1 (fr) Procédé de préparation de montélukast sodique
WO2008104957A2 (fr) Nouvelles formes polymorphes d'hydrochlorure de milnacipran
WO2013150544A2 (fr) Dispersion solide de chlorhydrate d'ivabradine
ITMI20090663A1 (it) Procedimento per la purificazione di paliperidone
CN103562203B (zh) 用于制备1-(2-甲基-4-(2,3,4,5-四氢-1-苯并吖庚因-1-基羰基)苄基氨基甲酰基-l-脯氨酸-n,n-二甲基酰胺的方法
JP2012020970A (ja) ｛２−アミノ−１，４−ジヒドロ−６−メチル−４−（３−ニトロフェニル）−３，５−ピリジンジカルボン酸３−（１−ジフェニルメチルアゼチジン−３−イル）エステル５−イソプロピルエステル｝の製造方法
EP2501674A2 (fr) Processus de préparation de formes polymorphes de lacosamide
JP2012506367A (ja) 結晶性モンテルカストの塩
US20120165527A1 (en) process for the preparation of pure paliperidone
KR101525296B1 (ko) 라미부딘 옥살레이트 및 이의 제조방법
CZ300692B6 (cs) Zpusob prípravy solifenacinu
CN115028672A (zh) 瑞德西韦中间体晶体及其制备方法
WO2009127996A1 (fr) Nouvelle forme cristalline de lamivudine
EP2448936A2 (fr) Procédés de préparation des formes i et ii de l'hydrochlorure de palonosétron
EP1740586A2 (fr) Formes cristallines de 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxydo-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
JP2011506427A (ja) ゾピクロンおよびその多形相の新規製造方法
EP3052499A1 (fr) Monohydrate de chlorhydrate d'abacavir de forme cristalline et procédé pour sa préparation
KR20090027483A (ko) 에스오메프라졸 유리염기의 무정형 고체의 개선된 제조방법
HK1226396B (zh) 用於大规模生产1-[(2-溴苯基)磺醯基]-5-甲氧基-3-[(4-甲基-1-呱嗪基)甲基]-1h-吲哚二甲磺酸盐一水合物的方法
HK1226396A1 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08763057

Country of ref document: EP

Kind code of ref document: A1